In one paragraphArticle in Journal of the National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
- Commented on by
- Commented on by
5 · Who and what moneyAuthors and funding
26 authors.
Yashasvini SampathkumarDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.ORCID 0009-0007-2120-2620 Ziad ZakariaDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Kelli O'ConnellDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.ORCID 0000-0002-4021-0788 Jenna BhimaniDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.ORCID 0000-0002-9962-7019 Victoria S BlinderDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.ORCID 0000-0002-1448-8671 Rachael BurganowskiKaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA, United States.ORCID 0009-0004-2179-9816 Isaac J ErgasDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, United States.ORCID 0000-0002-3187-9754 Grace B GallagherDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.ORCID 0009-0004-9277-5002 Jennifer J GriggsDepartment of Medicine, Division of Hematology/Oncology and Department of Health Management and Policy, University of Michigan, Ann Arbor, MI, United States.
Narre HeonDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.ORCID 0009-0003-5239-0821 Tatjana KolevskaDepartment of Oncology, Kaiser Permanente Medical Center, Vallejo, CA, United States.ORCID 0009-0003-5704-539X Yuriy KotsurovskyyDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.ORCID 0000-0002-1288-518X Candyce H KroenkeDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, United States.ORCID 0000-0002-6128-3118 Cecile A LaurentDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, United States.ORCID 0000-0001-9332-6971 Raymond LiuDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, United States.ORCID 0000-0002-4667-9632 Maria J Monroy-IglesiasDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.ORCID 0000-0003-2417-3275 Kanichi G NakataKaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA, United States.ORCID 0000-0001-6730-6045 Sonia PersaudDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.ORCID 0009-0008-5666-7994 Janise M RohDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, United States.ORCID 0000-0002-8615-4320 Sara TabatabaiDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.ORCID 0000-0002-5498-7176 Emily ValiceDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, United States.ORCID 0000-0003-2408-9727 Peng WangDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.ORCID 0000-0003-4303-6081 Elisa V BanderaCancer Epidemiology and Health Outcomes, Rutgers Cancer Institute, New Brunswick, NJ, United States.ORCID 0000-0002-8789-2755 Erin J Aiello BowlesKaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA, United States.ORCID 0000-0001-6287-7391 Lawrence H KushiDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, United States.ORCID 0000-0001-9136-1175 Elizabeth D KantorDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.ORCID 0000-0002-9124-5323 Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MRisk-based Imaging Strategies to Improve Breast Cancer Surveillance OutcomesP01CA154292 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Diana L Miglioretti · 2011 to 2026
$52.9MInfrastructure for Pathways, a Prospective Study of Breast Cancer SurvivorshipU01CA195565 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI AMBROSONE, CHRISTINE B., KUSHI, LAWRENCE H · 2016 to 2025
$18.8MCRN4: Cancer Research Resources & Collaboration in Integrated Health Care SystemsU24CA171524 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI KUSHI, LAWRENCE H · 2012 to 2016
$16.0MObesity, chemotherapy dosing, and breast cancer outcomesR37CA222793 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KANTOR, ELIZABETH DAVID · 2018 to 2024
$4.0MOncology-focused Postdoctoral Training in Care Delivery and Symptom Science (OPTICS)T32CA275764 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI JONINE L. BERNSTEIN, JUN J MAO · 2023 to 2026
$1.8MGroup Health Cancer Research Program Research Specialist AwardR50CA211115 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI BOWLES, ERIN JANELLE AIELLO · 2017 to 2021
$919kGeoffrey Beene Cancer Research Center at Memorial Sloan Kettering Cancer CenterNational Cancer Institute at the National Institutes of HealthNCI NIH HHS P01 CA154292NCI NIH HHS P30 CA008748NCI NIH HHS R37 CA222793NCI NIH HHS R50 CA211115NCI NIH HHS T32 CA275764NCI NIH HHS U01 CA195565NCI NIH HHS U24 CA171524P30CA008748 R50CA211115R37CA222793 P01CA154292R37CA222793 U01CA195565R37CA222793 U24CA171524T32CA275764
6 · The paper itselfAbstract
backgroundChemotherapy dose reductions are associated with poorer survival. To better understand the role of clinician- and facility-level factors in chemotherapy dosing, we conducted an analysis within a large, real-world cohort of women with stages I-IIIA breast cancer.
methodsOur cohort included 8540 breast cancer patients receiving chemotherapy at Kaiser Permanente Northern California between 2006 and 2019. Patients were treated across 22 facilities by 198 clinicians. We evaluated associations between clinician- and facility-level factors related to dose reductions at the start of chemotherapy (first cycle dose proportion, FCDP, <90%) and throughout treatment (average relative dose intensity, ARDI, <90%). Prevalence ratios (PR) and corresponding 95% confidence intervals (CI) were estimated for the clinician and facility factors in relation to chemotherapy dose reductions.
resultsFactors associated with an increased likelihood of dose reduction were increased clinician years since medical school (FCDP < 90%: PR≥30 vs. <10 years = 1.78, P-trend = .03; ARDI < 90%: PR≥30 vs <10 years = 1.29, P-trend = .03) and treatment at less urban facilities (ARDI < 90%: PR<100% vs 100% urban = 1.38, P-trend = .002). Factors associated with a decreased likelihood of dose reduction were higher annual clinician volume of stage I-IIIA breast cancer patients (FCDP < 90%: PR≥30 vs ≤15 patients = 0.64, P-trend = .03; ARDI < 90%: PR≥30 vs ≤15 patients = 0.76, P-trend = .01), higher treatment facility annual volume of stage I-IIIA breast cancer patients (ARDI < 90%: PR≥200 vs <75 patients = 0.85, P-trend = .03), and a larger practice size (FCDP < 90%: PR≥10 vs ≤5 oncologists = 0.53, P-trend = .02).
conclusionsClinician- and facility-level factors were associated with chemotherapy dose reductions. Practice-level changes, such as increasing breast cancer patient volumes and practice size, may support optimal dosing practices.
Indexed as
Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsDrug TaperingAdultAgedCaliforniaChemotherapy, AdjuvantFemaleHumansMiddle AgedNeoplasm Staging
Identifiers
PMID41782330
PMCPMC13033348
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390